Icad INC Form 4 insider transactions

ICAD, Inc. Director Hedvig Hricak's stock options were converted or terminated as a result of the company's merger with RadNet, Inc., which became effective on July 17, 2025.

ICAD Chief Technology Officer Jonathan Go's beneficial ownership of common stock and stock options ceased as ICAD Inc. merged with RadNet, Inc. on July 17, 2025.

A director of ICAD, Inc. disposed of all common stock and certain stock options as a result of the company's merger with RadNet, Inc. on July 17, 2025.

ICAD Chief Financial Officer Eric Lonnqvist has reported the complete disposition of his iCAD common stock and stock options, which were converted or terminated as a result of the company's merger with RadNet, Inc. effective July 17, 2025.

ICAD, Inc. President and CEO Dana Brown's shares and eligible stock options were converted into RadNet, Inc. stock and options following the merger effective July 17, 2025.

ICAD Director Rakesh Patel reported the complete disposition of his common stock and stock options in ICAD, Inc. due to the company's merger with RadNet, Inc. on July 17, 2025.

Director Andy Sassine's holdings in iCAD, Inc. were converted or terminated as a result of the company's merger with RadNet, Inc. on July 17, 2025.

ICAD Director Michael John Doyle reported the disposition of all his ICAD common stock and stock options as a result of the company's merger with RadNet, Inc., effective July 17, 2025.

Leading independent proxy advisory firms ISS and Glass Lewis have recommended iCAD stockholders vote FOR the proposed all-stock acquisition by RadNet, Inc., citing benefits for stockholders and accelerated deployment of AI solutions.

iCAD, Inc. is urging its stockholders to approve a definitive all-stock merger agreement with RadNet, highlighting the strategic benefits of combining AI-powered breast cancer detection solutions with RadNet's broader clinical AI portfolio and leveraging its scale for global expansion.

iCAD, Inc. has provided comprehensive details to its employees regarding its definitive all-stock merger agreement with RadNet, Inc., outlining the transaction terms and anticipated impacts on personnel and operations.

iCAD's Board of Directors approved an amendment to the exercise provisions of certain stock options in anticipation of the company's merger with RadNet.

RadNet, Inc. announces the acquisition of iCAD Inc., a leader in AI-powered breast health solutions, to enhance patient diagnosis and outcomes globally.

iCAD reported its Q1 2025 financial results, highlighting an increase in Annual Recurring Revenue (ARR) and announced a definitive agreement to be acquired by RadNet.

iCAD is collaborating with Microsoft to integrate its AI-powered mammography solutions into Microsoft's Precision Imaging Network (PIN), enhancing radiology reporting and workflow capabilities.

RadNet, Inc. plans to acquire iCAD, Inc., pending regulatory approvals and stockholder agreement, as detailed in a presentation to iCAD employees.

RadNet plans to acquire iCAD, seeking to combine their strengths in diagnostic imaging, AI, and digital health solutions to enhance cancer screening and detection.

RadNet's DeepHealth is set to acquire iCAD for $103 million in an all-stock transaction, aiming to enhance AI-powered breast cancer screening capabilities.

RadNet plans to acquire iCAD for approximately $103 million in stock, integrating it into its DeepHealth subsidiary to accelerate AI-powered breast cancer detection.

RadNet plans to acquire iCAD, pending regulatory approvals, to accelerate innovation and expand access to AI solutions in breast imaging.

RadNet is set to acquire iCAD in a stock-for-stock transaction, aiming to bolster its artificial intelligence capabilities in breast imaging and expand its market reach.

RadNet plans to acquire iCAD and integrate it into DeepHealth, RadNet's digital health business, to advance breast cancer screening.

RadNet plans to acquire iCAD for approximately $103 million in an all-stock deal to accelerate the adoption of AI in breast cancer screening.

RadNet plans to acquire iCAD to strengthen its DeepHealth leadership in AI-driven breast cancer solutions, expanding reach and enhancing financial performance.

Dana R Brown, President and CEO of ICAD INC, reports the acquisition of 11,483 shares of common stock to cover tax withholding requirements related to vested bonus shares.

Eric Lonnqvist, CFO of ICAD Inc., reports the acquisition of 7,345 common stock shares to cover tax obligations related to vested bonus shares.

RadNet, Inc. announces a definitive agreement to acquire iCAD, Inc., aiming to enhance AI-powered solutions in breast screening and expand its global reach.

RadNet has announced a definitive agreement to acquire iCAD, a leader in AI-powered breast health solutions, expected to close in the second or third quarter of 2025.

RadNet has entered into a definitive agreement to acquire iCAD, aiming to enhance AI-powered breast cancer detection and expand its global reach.

RadNet is hosting a media roundtable to discuss its acquisition of iCAD and the future of AI-powered early detection and diagnosis of breast cancer.